Biora Therapeutics, Inc. BIORQ
Set alert
At close · Oct 30
- YTD
- -99.95%
- 1 year
- -99.95%
- Open
- 0.0001
- Prev close
- 0.0001
- Mkt cap
- 452
- Vol
- 3.03K
- Avg vol
- 78
- EPS
- -0.01
- P/E
- 0.00
More statistics
- Low
- 0.0001
- High
- 0.0001
News
1 year ago globenewswire.com
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Testing in advanced animal model planned in Q4 f or smaller, 00-size BioJet device with largest capacity of any ingestible injectable
1 year ago globenewswire.com
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and…
2 years ago globenewswire.com
Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that it has entered into definitive…
2 years ago globenewswire.com
Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting
Expanded collaborations to support rapid testing in advanced animal models in Q4 2024 Expanded collaborations to support rapid testing in advanced animal models in Q4 2024
2 years ago globenewswire.com
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will participate in…
2 years ago seekingalpha.com
Biora Therapeutics, Inc. (BIOR) Q2 2024 Earnings Call Transcript
Biora Therapeutics, Inc. (BIOR) Q2 2024 Earnings Call Transcript
2 years ago globenewswire.com
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan
2 years ago globenewswire.com
Biora Therapeutics Announces Funding Agreement with Existing Investors
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced the signing of financing agreements with…
2 years ago globenewswire.com
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and…
2 years ago globenewswire.com
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical…
2 years ago globenewswire.com
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
Four device performance studies demonstrate the NaviCap platform's ability to deliver therapeutics directly to the colon under variable GI conditions.
2 years ago seekingalpha.com
Biora Therapeutics, Inc. (BIOR) Q1 2024 Earnings Call Transcript
Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Chuck Padala - Managing Director, LifeSci Advisors Adi Mohanty - Chief Executive…
2 years ago globenewswire.com
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in late Q2 2024 Clinical data on device function of the NaviCap™ platform to be presented…
2 years ago globenewswire.com
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and…
2 years ago globenewswire.com
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present clinical data…
2 years ago globenewswire.com
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
Dosing of all patients in the trial has been successfully completed Final results are expected to be available in late Q2 2024 SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc.…
2 years ago globenewswire.com
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent…
2 years ago globenewswire.com
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All NaviCap™ devices performed as intended and were well tolerated, with no…
2 years ago globenewswire.com
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously…
2 years ago globenewswire.com
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into…